Ferdinandos Skoulidis
Led CodeBreaK 100, the trial that made sotorasib the first approved KRAS inhibitor, and showed STK11/KEAP1 co-mutations blunt immunotherapy.
Overview
Ferdinandos Skoulidis was lead author of the phase 2 CodeBreaK 100 report that won sotorasib accelerated approval for KRAS G12C-mutant NSCLC, closing forty years of KRAS being undruggable. His earlier work showed that STK11 and KEAP1 co-mutations define an immunotherapy-resistant subgroup of KRAS-mutant lung cancer. He continues to lead KRAS combination trials at MD Anderson.
| Title | Journal | Year |
|---|---|---|
| Sotorasib for lung cancers with KRAS p.G12C mutation (CodeBreaK 100) | NEJM | 2021 |
| STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma | Cancer Discovery | 2018 |
Patients with KRAS G12C lung cancer that has progressed after chemo-immunotherapy can take an oral KRAS inhibitor instead of docetaxel and gain a somewhat longer time to progression with fewer severe side effects, but should understand that most tumours become resistant within a year and that survival is not improved. KRAS G12C testing is worthwhile, but first-generation inhibitors are a step rather than a cure; combinations and next-generation inhibitors are the active research fronts.
The most frequently mutated oncogene in cancer stopped being undruggable, and patients with KRAS G12C lung and bowel cancers now have targeted pills. The approach, exploiting a mutation-created chemical handle and an inactive-state pocket, has become a template for other hard targets.
Pages like this
not linked directly; found by shared links- PersonKevan M. Shokat
Shares Ostrem and Shokat: the hidden pocket that made KRAS G12C druggable, Adagrasib, Sotorasib, KRAS & RAS inhibitors.
- TrialKrascendo 1
Shares Adagrasib, Sotorasib, KRAS, Non-small-cell lung cancer.
- PersonD. Ross Camidge
Shares Non-small-cell lung cancer and the tags lung, targeted-therapy.
- TrialKRYSTAL-12
Shares Adagrasib, KRAS, Non-small-cell lung cancer.
- TermKRAS mutation subtypes (G12C, G12D, G12V)
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
- PersonJoe Y. Chang
Shares MD Anderson Cancer Center, Non-small-cell lung cancer and the tag lung.
- IdeaCovalent chemistry for the RAS mutations that still have no drug
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.
- RoadmapKRAS roadmap: undruggable → G12C → pan-RAS
Shares Adagrasib, Sotorasib, KRAS & RAS inhibitors, KRAS.